Targets the aging pathway directly.
Sirolimus inhibits mTOR, a key regulator of cellular growth and aging. Low, intermittent dosing promotes autophagy — the cellular cleanup process tied to longevity.

Longevity & Cognition
An mTOR inhibitor, dosed low and intermittently, researched for cellular cleanup and long-term healthspan.
Select treatment cycle
Subscription requiredTotal due now
$225.00
$225.00 per month · 1 Month
Prescription items are subject to physician review before dispensing. Once you check out, you'll get member portal access to complete a medical intake form. A licensed physician reviews it, and if you're approved, your medication ships. Your provider sets the exact dose during that review.
Understand the protocol

Sirolimus (Rapamycin)
Sirolimus inhibits mTOR, a key regulator of cellular growth and aging. Low, intermittent dosing promotes autophagy — the cellular cleanup process tied to longevity.
Healthy adults pursuing evidence-based longevity intervention, patients focused on healthspan and cellular aging, always under clinician supervision with periodic labs.
Sirolimus isn't a symptom drug — most patients feel nothing acute. Benefits show up through inflammatory markers, metabolic labs and biological age over six to twelve months.
Mental clarity and afternoon energy are the first things most patients report.
Sleep, stress tolerance and recovery even out. Effects accumulate rather than spike.
Follow-up markers give an objective read on whether the protocol is doing what it should.
This category is maintenance-driven. Benefit tracks with adherence over years, not weeks.
Timelines are typical ranges reported in clinical use and by Argo patients. Individual results vary with dose, adherence, baseline health and lifestyle.
Weekly
Intermittent dosing
mTOR
Pathway targeted
Lab-tracked
How results show

Fog has a short list of causes. We check all of them.
Fog has a short list of causes. We check all of them.
